Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
暂无分享,去创建一个
Pierre Grammond | Patrizia Sola | Guillermo Izquierdo | Jeannette Lechner-Scott | Helmut Butzkueven | Thor Petersen | Maria Trojano | Freek Verheul | Dana Horakova | Alessandra Lugaresi | Tim Spelman | Suzanne Hodgkinson | Pamela McCombe | Tomas Kalincik | Franco Granella | Roberto Bergamaschi | Cavit Boz | Gerardo Iuliano | Daniele Spitaleri | J. Lechner-Scott | M. Trojano | F. Grand'Maison | E. Havrdová | H. Butzkueven | R. Bergamaschi | G. Izquierdo | A. Lugaresi | C. Boz | P. Mccombe | P. Duquette | P. Sola | F. Granella | R. Hupperts | A. Prat | M. Girard | T. Spelman | D. Horáková | T. Kalincik | P. Grammond | V. van Pesch | T. Petersen | G. Iuliano | F. Verheul | M. Saladino | V. Jokubaitis | D. Farina | D. Paolicelli | P. Iaffaldano | E. Pucci | S. Hodgkinson | Marc Girard | Pierre Duquette | Alexandre Prat | C. Rózsa | Damiano Paolicelli | Eva Havrdova | J. Lorscheider | Johannes Lorscheider | D. Spitaleri | J. Olascoaga | Raymond Hupperts | François Grand'Maison | Eugenio Pucci | Vincent Van Pesch | Javier Olascoaga | Maria Laura Saladino | Csilla Rozsa | Vilija G Jokubaitis | Deborah Farina | Pietro Iaffaldano | C. Rozsa | Johannes Lorscheider
[1] A. Gustavsson,et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. , 2012, Journal of population therapeutics and clinical pharmacology = Journal de la therapeutique des populations et de la pharamcologie clinique.
[2] M. Daumer,et al. Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS , 2011, Neurology.
[3] C. Pozzilli,et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[4] M. Hutchinson,et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.
[5] Xuming He,et al. A Lack-of-Fit Test for Quantile Regression , 2003 .
[6] M. Hutchinson,et al. Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .
[7] A. Gustavsson,et al. Treatment experience, burden and unmet needs (TRIBUNE) in MS study: results from five European countries , 2012, Multiple sclerosis.
[8] O. Andersen,et al. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. , 1995, Brain : a journal of neurology.
[9] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[10] P. Gustafson,et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. , 2012, JAMA.
[11] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[12] L. Kappos,et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS , 2006, Neurology.
[13] S. Borg,et al. Costs and quality of life in multiple sclerosis patients with spasticity , 2014, Acta neurologica Scandinavica.
[14] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[15] B. Dr. C. Hirst MB,et al. Contribution of relapses to disability in multiple sclerosis , 2008, Journal of Neurology.
[16] P. Gustafson,et al. Practice of Epidemiology Marginal Structural Cox Models for Estimating the Association Between β-Interferon Exposure and Disease Progression in a Multiple Sclerosis Cohort , 2014 .
[17] G. Comi,et al. Freedom from disease activity in multiple sclerosis , 2010, Neurology.
[18] B. Haslinger,et al. Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta , 2013, Neuropsychiatric disease and treatment.
[19] L. Kappos,et al. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis , 2006, Multiple sclerosis.
[21] Deborah M. Miller,et al. Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. , 2010, Archives of neurology.
[22] J. Wolinsky,et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients , 2006, Multiple sclerosis.
[23] J. Lechner-Scott,et al. Predictors of disability worsening in clinically isolated syndrome , 2015, Annals of clinical and translational neurology.
[24] M. Trojano,et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. , 2007, Annals of neurology.
[25] J. Lechner-Scott,et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis , 2014, Multiple sclerosis.
[26] Pierre Grammond,et al. Defining reliable disability outcomes in multiple sclerosis. , 2015, Brain : a journal of neurology.
[27] M. Trojano,et al. New natural history of interferon‐β–treated relapsing multiple sclerosis , 2007 .
[28] L. Kappos,et al. Comparative efficacy of switching to natalizumab in active multiple sclerosis , 2015, Annals of clinical and translational neurology.
[29] R. Rudick,et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study , 2010, Multiple sclerosis.
[30] M. D'hooghe,et al. Pregnancy and multiple sclerosis: the influence on long term disability , 1994, Clinical Neurology and Neurosurgery.
[31] E. Granieri,et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNβ exposure in multiple sclerosis , 2006, Multiple sclerosis.
[32] B. Cree,et al. Disease activity free status: a new end point for a new era in multiple sclerosis clinical research? , 2014, JAMA neurology.
[33] Richard A. C. Hughes,et al. PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.
[34] L. Roccatagliata,et al. Surrogate endpoints for EDSS worsening in multiple sclerosis , 2010, Neurology.
[35] L. Kappos,et al. Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15 , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[36] M. Sylvestre,et al. Does pregnancy alter the long-term course of multiple sclerosis? , 2014, Annals of epidemiology.
[37] Dana Horakova,et al. Volumetric MRI Markers and Predictors of Disease Activity in Early Multiple Sclerosis: A Longitudinal Cohort Study , 2012, PloS one.
[38] J. Byrnes,et al. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.
[39] M. Stromillo,et al. Refining response to treatment as defined by the Modified Rio Score , 2013, Multiple sclerosis.
[40] J. Lechner-Scott,et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. , 2015, JAMA neurology.
[41] Jeffrey A. Cohen,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. , 1995, Neurology.
[42] R. Rudick,et al. Predictors of long‐term outcome in multiple sclerosis patients treated with interferon beta , 2013, Annals of neurology.
[43] J. W. Rose,et al. Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis , 1995, Neurology.
[44] P. Adeleine,et al. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. , 2003, Brain : a journal of neurology.
[45] L. Kappos,et al. Impact of exposure to interferon beta-1a on outcomes in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS long-term follow-up study , 2011, Therapeutic advances in neurological disorders.
[46] Yinshan Zhao,et al. Impact of multiple sclerosis relapses on progression diminishes with time , 2009, Neurology.
[47] R. Rudick,et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients , 2005, Multiple sclerosis.
[48] B. Taylor,et al. The economic impact of multiple sclerosis in Australia in 2010 , 2013, Multiple sclerosis.
[49] P. Duquette,et al. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. , 1993 .
[50] G. Nagels,et al. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis , 2012, Journal of Neurology.
[51] F. Lublin,et al. Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.